The DiRECT Trial & NHS Low Calorie Diet Programme: A GP Implementation Guide
From the landmark remission trial to practical referral — how to deliver T2DM remission in primary care
The DiRECT trial overturned decades of clinical nihilism about Type 2 diabetes — proving that remission is achievable through structured weight loss alone. 46% of participants achieved T2DM remission at one year without any glucose-lowering medication. The NHS Low Calorie Diet Programme now makes this intervention available to GPs across England. This guide covers the trial protocol, the biological mechanism, patient selection, referral pathway, and how to manage the consultation.
Clinical Decision Support: This article is for educational purposes and supports — not replaces — clinical judgment. Always verify with current national guidelines, BNF, and specialist consultation when needed.
In 2017, the Diabetes Remission Clinical Trial (DiRECT) published results that fundamentally changed what GPs could offer patients with Type 2 diabetes. The trial demonstrated that 46% of participants achieved T2DM remission — defined as HbA1c below 48 mmol/mol sustained for at least 12 months without any glucose-lowering medication — through a structured weight management programme delivered entirely in primary care. At two years, 36% remained in remission. These were not exceptional patients in a specialist centre; they were ordinary people with T2DM managed by their GP. The DiRECT trial did not just prove that remission was possible — it proved that GPs could deliver it. This guide gives you the clinical tools to do exactly that.
The DiRECT Trial: What Was Actually Done
DiRECT was a cluster-randomised controlled trial conducted across 49 primary care practices in Scotland and Tyneside, led by Professor Roy Taylor (Newcastle University) and Professor Mike Lean (University of Glasgow). It enrolled 306 adults aged 20–65 years with T2DM diagnosed within the previous 6 years and BMI 27–45 kg/m². Practices were randomised to either the intervention (Counterweight-Plus weight management programme) or best-practice care as usual. The intervention was delivered by practice nurses and dietitians — not hospital specialists.
The Three-Phase Protocol
| Phase | Duration | What Happened | Clinical Goal |
|---|---|---|---|
| Phase 1: Total Diet Replacement | Weeks 1–20 (12–20 weeks) | All food replaced with formula products (soups, shakes, bars) providing 825–853 kcal/day. All diabetes and antihypertensive medications stopped at day 1. | Rapid weight loss of 10–15 kg; hepatic and pancreatic fat depletion |
| Phase 2: Food Reintroduction | Weeks 20–32 (2–8 weeks) | Gradual reintroduction of food over 2–8 weeks using a structured meal plan. Formula products phased out progressively. | Maintain weight loss; establish sustainable eating pattern |
| Phase 3: Long-Term Maintenance | Months 9–24+ | Monthly structured support sessions with practice nurse or dietitian. Cognitive behavioural strategies for weight maintenance. Physical activity programme. | Prevent weight regain; sustain remission |
A critical and often overlooked feature of the DiRECT protocol: ALL glucose-lowering medications were stopped on Day 1 of the total diet replacement phase. This was not a gradual wean — it was an immediate cessation. Antihypertensives were also stopped or reduced. This was safe because the very low calorie intake rapidly reduces blood glucose and blood pressure within days.
The Results: What DiRECT Actually Proved
| Outcome | Intervention Group | Control Group | Clinical Significance |
|---|---|---|---|
| T2DM remission at 12 months | 46% | 4% | 11× higher remission rate — the most effective non-surgical intervention ever trialled |
| T2DM remission at 24 months | 36% | 3% | Sustained remission — not just a transient effect |
| Mean weight loss at 12 months | 10.0 kg | 1.0 kg | 9 kg greater weight loss in intervention group |
| ≥15 kg weight loss achieved | 24% | 0% | Highest weight loss subgroup: 86% remission rate |
| ≥10 kg weight loss achieved | 57% | 0% | 57% remission rate in this subgroup |
| Medication-free at 12 months | 74% | 18% | Most intervention participants off all diabetes drugs |
| Quality of life improvement | Significant | None | Validated EQ-5D scores improved substantially |
The dose-response relationship between weight loss and remission is the most clinically important finding from DiRECT. Participants who lost ≥15 kg had an 86% remission rate. Those who lost 10–15 kg had a 57% remission rate. Even 5–10 kg weight loss produced a 34% remission rate. There is no threshold below which weight loss has no benefit — every kilogram matters.
The Biology: Why Rapid Weight Loss Reverses T2DM
The DiRECT trial was built on the Twin Cycle Hypothesis, developed by Professor Roy Taylor over two decades of research. The hypothesis proposes that T2DM is caused by two interconnected cycles of ectopic fat accumulation — one in the liver and one in the pancreas — both of which are reversible with sufficient weight loss.
The Liver Cycle: Insulin Resistance
Excess caloric intake drives fat accumulation in the liver (hepatic steatosis). Hepatic fat causes hepatic insulin resistance — the liver fails to suppress glucose output in the fasted state, producing fasting hyperglycaemia. Hepatic fat also drives overproduction of VLDL triglycerides, which are exported to the pancreas. In the DiRECT trial, MRI-quantified liver fat fell from a mean of 16% to 3% (normal) within 8 weeks of starting the total diet replacement — before significant weight loss had occurred. This rapid reduction in liver fat was the first step in breaking the cycle.
The Pancreas Cycle: Beta-Cell Dysfunction
VLDL-derived fat accumulates in the pancreas, impairing beta-cell insulin secretion. This is the second cycle. Critically, pancreatic fat accumulation is not a permanent structural change — it is a functional impairment that reverses with fat removal. In the DiRECT COUNTERPOINT study, pancreatic fat fell from 8% to 6% (normal) after 8 weeks of very low calorie diet, and first-phase insulin secretion — the rapid insulin spike that normally occurs within 2 minutes of eating — was restored. This restoration of first-phase insulin response is the biological signature of T2DM remission.
The Twin Cycle Hypothesis explains why remission is most achievable in patients with shorter T2DM duration. After many years of T2DM, beta-cell mass is progressively lost through apoptosis — a process that is not reversible with weight loss alone. This is why DiRECT enrolled patients with T2DM diagnosed within 6 years, and why the NHS LCD Programme targets patients diagnosed within 6 years.
The NHS Low Calorie Diet Programme: What It Is and How to Refer
Following the DiRECT trial results, NHS England commissioned a national implementation programme — the NHS Type 2 Diabetes Path to Remission Programme (commonly called the NHS Low Calorie Diet Programme or NHS LCD Programme). It is now available across England and is the most direct translation of the DiRECT protocol into routine primary care. GPs can refer eligible patients directly.
Eligibility Criteria
| Criterion | Requirement | Notes |
|---|---|---|
| T2DM diagnosis | Confirmed T2DM | Not Type 1, MODY, or secondary diabetes |
| Duration of T2DM | Diagnosed within the last 6 years | Longer duration = lower remission likelihood due to beta-cell loss |
| BMI | ≥27 kg/m² (general population) | ≥25 kg/m² for South Asian, Chinese, and Black African patients |
| Age | 18–65 years | Upper age limit reflects DiRECT trial population; older patients may be considered case-by-case |
| HbA1c | 48–108 mmol/mol (6.5–12%) | Very high HbA1c (>108 mmol/mol) may require stabilisation first |
| Medications | Not on insulin | Patients on insulin require specialist input before LCD; sulphonylureas require dose reduction |
| Exclusion criteria | Pregnancy, active eating disorder, recent bariatric surgery, severe renal/hepatic disease, active cancer | Screen carefully before referral |
What the Programme Delivers
- Phase 1 (12 weeks): Total diet replacement at 800–900 kcal/day using commercially available formula products (soups, shakes, bars). All food is replaced — no conventional meals during this phase.
- Phase 2 (4–8 weeks): Structured food reintroduction with dietitian support. Formula products gradually replaced with whole foods following a Mediterranean-style eating pattern.
- Phase 3 (up to 12 months total): Long-term weight maintenance support including group sessions, one-to-one coaching, physical activity guidance, and psychological support for behaviour change.
- Digital delivery: The programme is delivered primarily digitally (app-based with video consultations) — accessible from home, reducing barriers for working patients.
- Medication management: The programme team works with the GP to manage medication changes — GPs receive clear guidance on when and how to reduce diabetes and antihypertensive medications.
How to Refer
- Referral is made via the NHS Diabetes Prevention Programme referral pathway — check your local ICB (Integrated Care Board) for the specific referral route in your area
- In most areas, referral can be made directly from EMIS/SystmOne using the NHS DPP referral template
- Patients can also self-refer via the NHS website (nhs.uk/better-health/lose-weight) — signpost patients to this option
- The programme is free to eligible patients — there is no cost for the formula products or coaching sessions
- Waiting times vary by area — typically 4–12 weeks from referral to programme start
The GP Consultation: How to Have the Remission Conversation
Many GPs feel uncertain about raising T2DM remission as a treatment goal — either because they are unfamiliar with the evidence, or because they worry about raising false hope. The evidence is now robust enough to make remission an explicit, evidence-based treatment goal for eligible patients. The consultation framework below helps structure this conversation in a way that is honest, motivating, and clinically accurate.
Opening the Conversation
- "I want to share something with you that I think could make a real difference to your diabetes — would that be okay?"
- "There's now strong evidence from a large clinical trial that Type 2 diabetes can go into remission — meaning your blood sugar returns to normal without any medication — through a structured weight loss programme. This isn't a cure, but it is a genuine possibility for people in your situation."
- "The trial showed that about half of people who completed the programme were in remission at one year. The more weight lost, the higher the chance — but even modest weight loss significantly reduces your medication burden."
- "This is a demanding programme — it involves replacing all your food with formula products for 12 weeks. It's not easy, but the results are remarkable. Would you like to know more?"
Addressing Common Patient Questions
| Patient Question | Evidence-Based Answer |
|---|---|
| "Will my diabetes come back?" | "Remission is sustained as long as the weight loss is maintained. In the DiRECT trial, 36% were still in remission at 2 years. Weight regain is the main cause of relapse — the programme includes long-term maintenance support to help prevent this." |
| "Do I have to stop my medication?" | "Yes — on Day 1 of the formula phase, your diabetes medication will be stopped. This is safe because the very low calorie intake rapidly reduces blood sugar. We'll monitor you closely and restart medication if needed." |
| "What if I can't manage 12 weeks on shakes?" | "The programme has a high completion rate — about 70–80% in the DiRECT trial. The formula products are nutritionally complete and most people find the hunger settles after the first week. You'll have regular support throughout." |
| "Is this available on the NHS?" | "Yes — the NHS Low Calorie Diet Programme is free for eligible patients. I can refer you today, and you'll typically start within a few weeks." |
| "What if I don't achieve remission?" | "Even if full remission isn't achieved, significant weight loss will reduce your HbA1c, lower your blood pressure, reduce your medication burden, and reduce your cardiovascular risk. There is no scenario where meaningful weight loss doesn't benefit you." |
Medication Safety: The Most Important Clinical Task
Medication management is the highest-risk aspect of the NHS LCD Programme for GPs. The very low calorie intake (800–900 kcal/day) produces rapid and significant reductions in blood glucose and blood pressure within days of starting. Failure to proactively reduce or stop medications will result in hypoglycaemia and hypotension. This is not a theoretical risk — it is a predictable, preventable harm.
Diabetes Medication Protocol
| Medication | Action at Programme Start | Rationale | Monitoring |
|---|---|---|---|
| Metformin | Continue at current dose | No hypoglycaemia risk; may reduce GI side effects of formula products | Routine monitoring |
| Sulphonylureas (gliclazide, glimepiride) | STOP on Day 1 | High hypoglycaemia risk with very low calorie intake | Daily glucose monitoring for first 2 weeks; restart only if HbA1c rises above 48 mmol/mol |
| SGLT2 inhibitors (empagliflozin, dapagliflozin) | STOP on Day 1 | Risk of euglycaemic DKA with very low carbohydrate intake; also diuretic effect may cause dehydration | Restart after food reintroduction phase if clinically indicated |
| GLP-1 agonists (semaglutide, liraglutide) | STOP on Day 1 | Additive nausea with formula products; appetite suppression already achieved by LCD | Reassess need after programme completion |
| DPP-4 inhibitors (sitagliptin, alogliptin) | STOP on Day 1 | No hypoglycaemia risk but no additional benefit during TDR phase | Reassess after programme |
| Insulin | Specialist input required | Complex dose adjustment needed; not suitable for standard LCD referral without specialist involvement | Refer to diabetes team before programme start |
Antihypertensive Medication Protocol
- Blood pressure falls rapidly with very low calorie intake — typically 5–10 mmHg systolic within the first week
- Reduce antihypertensive doses by 50% on Day 1 if baseline BP is well-controlled (systolic <140 mmHg)
- Stop antihypertensives entirely on Day 1 if baseline BP is borderline-low (systolic <130 mmHg) or if patient is on multiple agents
- Advise patient to monitor BP at home daily for the first 2 weeks and contact the practice if systolic falls below 100 mmHg or they feel dizzy/lightheaded
- Diuretics (furosemide, indapamide) carry particular risk of dehydration during TDR — consider stopping or halving dose
- ACE inhibitors and ARBs: monitor renal function at 2 weeks if dose unchanged — rapid weight loss can alter renal haemodynamics
Never start a patient on the NHS LCD Programme without a medication review and clear written instructions about which medications to stop or reduce on Day 1. The programme team will also advise on this, but the GP retains clinical responsibility for medication safety. Document the medication plan in the patient record before referral.
Monitoring During the Programme: GP Responsibilities
| Timepoint | What to Check | Action if Abnormal |
|---|---|---|
| Day 1 (programme start) | Baseline HbA1c, eGFR, electrolytes, BP, weight | Ensure medication plan documented; confirm eligibility |
| Week 2 | BP (home readings), glucose (if on SU/insulin), symptoms of hypoglycaemia or hypotension | Adjust medications if BP <100 systolic or hypoglycaemia occurring |
| Week 4 | Weight, BP, glucose, symptoms | Reassess medication needs; encourage if weight loss on track |
| Week 12 (end of TDR phase) | HbA1c, eGFR, electrolytes, BP, weight, lipids | Assess remission status; plan food reintroduction phase medications |
| Month 6 | HbA1c, weight, BP, lipids, eGFR | Confirm remission if HbA1c <48 mmol/mol; document in records |
| Month 12 | HbA1c, weight, BP, full metabolic panel | Confirm sustained remission; plan long-term maintenance strategy |
| Annually thereafter | HbA1c, weight, BP, lipids, eGFR, ACR | Monitor for relapse; restart diabetes medication if HbA1c ≥48 mmol/mol |
What Happens After the Programme: Long-Term Maintenance
The DiRECT trial demonstrated that weight regain is the primary driver of remission relapse. At 2 years, participants who maintained ≥10 kg weight loss had a 64% remission rate, while those who regained weight had a remission rate approaching zero. Long-term weight maintenance is therefore not a lifestyle aspiration — it is a clinical necessity for sustained remission. GPs play a central role in supporting this.
The Maintenance Consultation Framework
- Weigh at every diabetes review — weight is now a vital sign for patients in remission; a gain of ≥3 kg should trigger a proactive conversation
- Celebrate and reinforce: "Your HbA1c is still in the normal range — you've achieved something remarkable. Let's talk about what's been working."
- Identify early warning signs of relapse: increased appetite, return of cravings, weight gain, rising HbA1c (even within normal range)
- Dietary pattern post-programme: Mediterranean-style eating is the most evidence-based long-term maintenance diet — high in vegetables, legumes, fish, olive oil; low in ultra-processed foods and refined carbohydrates
- Physical activity: Resistance training 2–3 times/week is particularly important for weight maintenance — preserves muscle mass and maintains resting metabolic rate
- Consider GLP-1 agonist for weight maintenance if weight regain begins — semaglutide or tirzepatide can be used as maintenance pharmacotherapy after LCD-induced remission
Defining and Documenting Remission
- Remission definition (ADA/Diabetes UK 2021 consensus): HbA1c <48 mmol/mol measured at least 3 months after stopping all glucose-lowering medication
- Document remission clearly in the patient record — use the SNOMED code for "Type 2 diabetes mellitus in remission" (428896009)
- Inform the patient in writing — a letter confirming remission is motivating and provides a record for insurance and employment purposes
- Do not remove the T2DM diagnosis from the record — remission is not a cure; the underlying susceptibility remains and the diagnosis should be retained
- Annual HbA1c monitoring is mandatory for all patients in remission — relapse can occur silently without symptoms
- Notify the diabetes register — patients in remission should remain on the QOF diabetes register for monitoring purposes
Beyond DiRECT: Other Evidence-Based LCD Approaches
The DiRECT protocol is not the only evidence-based approach to T2DM remission through dietary intervention. Several other programmes and dietary strategies have demonstrated meaningful remission rates and are available to GPs as alternatives or complements to the NHS LCD Programme.
| Programme / Approach | Protocol | Remission Rate | Availability | Best For |
|---|---|---|---|---|
| NHS LCD Programme (DiRECT-based) | 800–900 kcal/day TDR for 12 weeks + structured support | ~46% at 12 months | Free via NHS referral | T2DM <6 years; BMI ≥27; motivated patients |
| Low-carbohydrate diet (<130 g/day) | Self-directed or dietitian-supported; no calorie restriction required | 10–20% remission at 12 months | GP advice + Diabetes UK resources | Patients who cannot commit to TDR; longer T2DM duration |
| Intermittent fasting (5:2 or 16:8) | 2 days/week at 500–600 kcal; or 16-hour daily fast | 15–25% remission in small trials | Self-directed; limited NHS support | Patients who prefer flexibility; not suitable in eating disorders |
| Very low carbohydrate ketogenic diet | <50 g carbohydrate/day; high fat, moderate protein | 20–30% remission in observational studies | Self-directed; Virta Health (private) | Patients with strong preference; requires close monitoring |
| Structured commercial programmes (Oviva, Second Nature) | App-based dietary coaching + behavioural support | 15–25% remission in real-world data | NHS-approved; some areas free via referral | Digitally engaged patients; lower intensity than TDR |
For patients who are not eligible for or do not want the NHS LCD Programme, a low-carbohydrate diet is the most accessible alternative. Diabetes UK provides free patient resources at diabetes.org.uk/guide-to-diabetes/enjoy-food/eating-with-diabetes/what-is-a-healthy-balanced-diet/low-carb-diets. The key medication safety point is the same: reduce sulphonylureas by 50% at initiation and monitor glucose daily.
Special Considerations: Who May Not Be Suitable
- T2DM duration >6 years: Remission is less likely due to progressive beta-cell loss, but significant metabolic benefit (HbA1c reduction, medication reduction, cardiovascular risk reduction) is still achievable — do not withhold the programme on this basis alone
- Active eating disorder (anorexia, bulimia, BED): Total diet replacement is contraindicated — refer to eating disorder service first; consider low-carbohydrate approach with psychological support instead
- Severe depression or psychiatric illness: Assess stability before referral; the programme requires significant motivation and self-management capacity; involve mental health team
- Frailty and older adults (>65 years): Risk of sarcopenia with rapid weight loss; ensure adequate protein intake (≥1.2 g/kg/day); consider resistance exercise programme alongside LCD; involve geriatrics if frailty score ≥4
- Severe renal impairment (eGFR <30): High protein formula products may worsen renal function; seek nephrology advice before referral
- Pregnancy or planning pregnancy: Contraindicated; advise effective contraception before starting; stop programme immediately if pregnancy occurs
The Bigger Picture: Remission as a Public Health Opportunity
The NHS LCD Programme represents one of the most cost-effective interventions in modern primary care. A health economic analysis of the DiRECT trial estimated that the programme costs approximately £1,000 per patient — compared to the lifetime cost of T2DM management (medications, monitoring, complications) estimated at £25,000–£50,000 per patient. If even 10% of the 4.3 million people with T2DM in England were eligible and achieved remission, the NHS would save billions of pounds annually while dramatically improving patient quality of life. The barrier is not evidence — it is awareness and referral. Every GP who refers one eligible patient to the NHS LCD Programme is making a meaningful contribution to this public health opportunity.
The NHS LCD Programme is currently available in most areas of England. Check your local ICB website or the NHS England Diabetes Prevention Programme page for the referral pathway in your area. If the programme is not yet available locally, the NHS Diabetes Prevention Programme (NDPP) — which targets pre-diabetes — is available nationally and can be used as an interim referral for patients with pre-diabetes or early T2DM.
Key Clinical Takeaways
- DiRECT proved T2DM remission is achievable in primary care: 46% remission at 12 months, 36% at 24 months — through structured weight loss alone, delivered by practice nurses and dietitians
- The dose-response is clear: ≥15 kg weight loss → 86% remission; ≥10 kg → 57%; 5–10 kg → 34% — every kilogram of weight loss matters
- NHS LCD Programme eligibility: T2DM diagnosed within 6 years, BMI ≥27 (≥25 in South Asian patients), HbA1c 48–108 mmol/mol, not on insulin — refer directly via NHS DPP pathway
- Medication safety is the highest-risk task: STOP sulphonylureas, SGLT2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors on Day 1; CONTINUE metformin; REDUCE antihypertensives by 50%
- Document remission using SNOMED code 428896009; retain T2DM diagnosis on record; monitor HbA1c annually — relapse is silent and common with weight regain
- Long-term maintenance is the clinical challenge: weigh at every review; Mediterranean diet + resistance exercise; consider GLP-1 agonist if weight regain begins
- For patients not eligible for NHS LCD: low-carbohydrate diet (<130 g/day) is the most accessible alternative — Diabetes UK endorses it and provides free patient resources
You might also like
Type 2 Diabetes in Primary Care: From Diagnosis to Insulin Initiation
Type 2 diabetes affects over 537 million adults globally. This guide covers the complete GP management pathway — from HbA1c-based diagnosis and lifestyle intervention through metformin initiation, SGLT2 inhibitors, GLP-1 agonists, and insulin initiation protocols.
Diabetes Lifestyle Management: Beyond the Prescription Pad
Pharmacotherapy alone cannot reverse the trajectory of Type 2 diabetes. Structured lifestyle intervention — encompassing dietary pattern, physical activity, sleep quality, stress physiology, and behaviour change science — can reduce HbA1c by up to 22 mmol/mol and achieve remission in a significant proportion of patients. This guide gives GPs the clinical tools to prescribe lifestyle with the same precision as medication.
Obesity & Weight Management in Primary Care: A Complete Clinical Framework
Obesity is a chronic, relapsing, neurobiological disease — not a lifestyle choice. The Edmonton Obesity Staging System reframes obesity management around functional impairment rather than BMI alone. GLP-1 receptor agonists have transformed pharmacotherapy, achieving 15–22% weight loss in trials. This guide gives GPs the clinical framework to assess, stage, treat, and refer patients with obesity using the best available evidence.